Scholarlink

<p><sup>225</sup>Ac is a highly sought-after but scarce radionuclide for targeted alpha-therapy with weak gamma-lines. For preclinical studies, it is more convenient to use beta- and gamma-emitting isotope <sup>228</sup>Ac (T<sub>1/2</sub> = 6.15&#xa0;h), which is contained in the generator pair <sup>228</sup>Ra/<sup>228</sup>Ac (T<sub>1/2</sub> <sup>228</sup>Ra = 5.75 y) in the decay chain of natural <sup>232</sup>Th. We have developed a simple, fast, and effective method for the repeated separation of <sup>228</sup>Ac from aged thorium nitrate. This method has been tested on 350&#xa0;g of thorium nitrates, from which we obtained 0.11&#xa0;MBq of <sup>228</sup>Ra, and subsequently isolated <sup>228</sup>Ac 20 times with a yield of 96% and high degree of purity. The concept of providing an almost unlimited source of <sup>228</sup>Ac using the proposed method was demonstrated, meaning it can be used for decades provided the source thorium is periodically reprocessed to produce new supplies of source <sup>228</sup>Ra. Given the high abundance of legacy thorium sources with accumulated decay products, the method seems promising for the development of <sup>225</sup>Ac-based radiopharmaceuticals using <sup>228</sup>Ac.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An infinite actinium-228 generator as an indispensable tool for nuclear medicine purposes

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Andrey G. Kazakov,
  • Taisya Y. Ekatova,
  • Denis N. Dogadkin,
  • Vladimir P. Kolotov,
  • Sergey E. Vinokurov,
  • Boris F. Myasoedov

摘要

225Ac is a highly sought-after but scarce radionuclide for targeted alpha-therapy with weak gamma-lines. For preclinical studies, it is more convenient to use beta- and gamma-emitting isotope 228Ac (T1/2 = 6.15 h), which is contained in the generator pair 228Ra/228Ac (T1/2 228Ra = 5.75 y) in the decay chain of natural 232Th. We have developed a simple, fast, and effective method for the repeated separation of 228Ac from aged thorium nitrate. This method has been tested on 350 g of thorium nitrates, from which we obtained 0.11 MBq of 228Ra, and subsequently isolated 228Ac 20 times with a yield of 96% and high degree of purity. The concept of providing an almost unlimited source of 228Ac using the proposed method was demonstrated, meaning it can be used for decades provided the source thorium is periodically reprocessed to produce new supplies of source 228Ra. Given the high abundance of legacy thorium sources with accumulated decay products, the method seems promising for the development of 225Ac-based radiopharmaceuticals using 228Ac.